News

BridgeBio Pharma Highlights ATTRibute-CM Data at 2025 ESC Congress

BridgeBio Pharma Highlights ATTRibute-CM Data at 2025 ESC Congress

Overview of BridgeBio Pharma's Contribution at ESC Congress 2025

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a pioneering biopharmaceutical company dedicated to advancing treatment solutions for genetic diseases, is scheduled to make a significant impact at the upcoming European Society of Cardiology (ESC) Congress 2025. This prestigious event will be noted for showcasing new research developments and innovative therapeutic options, and BridgeBio will take center stage with multiple presentations centered on their groundbreaking ATTRibute-CM study.

Key Presentations During the ESC Congress 2025

Rapid-Fire Oral Presentation

Among the highlights for BridgeBio is a rapid-fire oral presentation that will provide exciting insights into the open-label extension data from the ATTRibute-CM study. This presentation will illustrate several critical findings, including the effects of Acoramidis on cardiovascular mortality rates at the 42-month mark, discussed by leading expert Kevin Alexander, M.D., from Stanford University School of Medicine.

ePosters on Innovative Findings

In addition to the oral presentation, two ePosters will delve into pertinent topics that emerged during the ATTRibute-CM study. Nitasha Sarswat, M.D. from UChicago Medicine, will present findings regarding the impact of Acoramidis on NT-proBNP levels at Month 30. This data aims to better understand how Acoramidis may contribute to improved cardiac health outcomes compared to placebo treatments.

Furthermore, Julian Gillmore, M.D., Ph.D., from University College London, will highlight the results indicating a beneficial effect of Acoramidis on patients with ATTR-CM, measuring changes from baseline in NAC ATTR Stage at Month 30. These well-structured studies offer a comprehensive view of Acoramidis' effectiveness.

Understanding Acoramidis and Its Implications

Acoramidis, marketed as Attruby™, is a transthyretin stabilizer developed for the treatment of cardiac amyloidosis (ATTR-CM). Its clinical goal is to reduce cardiovascular death and related hospitalizations in adults. The promising data surrounding Acoramidis underscores its potential in managing this challenging condition.

Safety Profile of Attruby™

As with any treatment, understanding the safety profile is crucial. Noteworthy adverse reactions associated with Attruby include diarrhea, which occurs at a rate of 11.6% compared to 7.6% in placebo, and upper abdominal pain occurring in 5.5% of patients. Fortunately, most side effects reported in clinical trials were mild and manageable, with discontinuation rates similar to those of placebo group participants.

BridgeBio's Commitment to Genetic Medicine

Founded in 2015, BridgeBio Pharma is on the forefront of biopharmaceutical innovation, striving to deliver transformative medicines for genetic diseases. The company’s mission is rooted in applying cutting-edge science to develop treatments that can significantly improve the lives of patients. The team's extensive expertise in drug discovery and development embodies their commitment to advancing genetic therapies promptly.

Staying Informed about BridgeBio

To stay updated on their latest developments, individuals can visit BridgeBio's official website and follow them across various social media platforms like LinkedIn, Twitter, and Facebook. Keeping abreast of their research achievements can provide deeper insights into how they are shaping the future of medicine.

Contact Information

For media inquiries or to gain further insights into BridgeBio's advancements, you may reach out to their media contact, Bubba Murarka, Executive Vice President, Corporate Development, at contact@bridgebio.com or call (650)-789-8220. Additionally, their investor relations contact, Chinmay Shukla, Senior Vice President, Strategic Finance, can be reached at ir@bridgebio.com.

Frequently Asked Questions

What is the significance of the ATTRibute-CM study?

The study evaluates the efficacy and safety of Acoramidis in treating patients with ATTR-CM, focusing on critical health outcomes such as cardiovascular mortality.

Who will present the data at the ESC Congress?

The data will be presented by notable professionals, including Kevin Alexander, M.D., and Nitasha Sarswat, M.D., among others.

What is Acoramidis, and how does it work?

Acoramidis is a transthyretin stabilizer aimed at treating the cardiomyopathy associated with transthyretin-mediated amyloidosis, helping to stabilize proteins and reduce symptoms.

What adverse reactions are linked to Acoramidis?

Common reactions include diarrhea and upper abdominal pain; however, they typically resolve without treatment discontinuation.

How can I learn more about BridgeBio Pharma?

Visit their official website or follow them on LinkedIn, Twitter, and Facebook for the latest news and updates on their projects and findings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Deadline Looms for EquipmentShare Investors' Legal Action

Updated Category News Views 1

Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....

Continue Reading
Cannabis Industry Pushes for Robust Financial Services

Updated Category News Views 3

Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...

Continue Reading
Albertsons Welcomes Once Upon a Coconut Nationwide

Updated Category News Views 1

Coconut Water Takes Over Grocery Aisles You know, for all the cautious optimism I wield, this here is a move that shows real muscle in the world of coconut water—I mean, slamming into Albertsons' grocery empire is no small potatoes! Once Upon a Coconut has landed its premium hydration cans across all the banners under this giant retailer. From that good ol' familiar...

Continue Reading
Helio Fred Garcia Honored by Diversity Action Alliance

Updated Category News Views 1

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Continue Reading
WNET's 25th Anniversary 9/11 Tribute: Stories and Lessons

Updated Category News Views 3

Reflecting on a Dark Day with WNET's Programming Nothing quite hits you like the anniversary of a colossal tragedy. The memories of September 11, 2001, remain etched in the urban landscape of New York City, and this year marks 25 years since that heart-wrenching day. The WNET Group steps up to the plate with a comprehensive slate of programming aimed at honoring the...

Continue Reading
Woodpack Global Unveils Crate Design System: A New Era Begins

Updated Category News Views 2

Innovating the Wooden Crate Landscape An old industry got a much-needed facelift today, folks. Woodpack Global has rolled out Crate Design System™ (CDS)—a snazzy new tool that's shaking up the wooden crate design landscape. It blows the dust off outdated design methods that have been collecting cobwebs since the '60s. That's right, we’re talking about a significant...

Continue Reading
Sandbox VR Expands to Melbourne, Betting on Immersive Fun

Updated Category News Views 3

Sandbox VR Ventures into Melbourne's Heart Every now and then, a venture takes its ambitions and rolls the dice on a prime location. Sandbox VR is swaggering into Melbourne's bustling Central Business District, fresh out of its success on the Gold Coast. Opening this Melbourne venue on September 14 marks a significant leap in the company's Aussie expansion—a bold nod to...

Continue Reading
Navigating Land Access: The Hidden Roadblock in Mining

Updated Category News Views 1

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 1

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 1

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading

Top 5 Most Recently Viewed Articles

Stuart Therapeutics Reveals Promising Phase III Results for ST-100

Updated Category News Views 111

Exciting Developments from Stuart Therapeutics Stuart Therapeutics is making waves in the ophthalmology field with their latest announcement concerning ST-100, also known as Vezocolmitide. This innovative ophthalmic solution is under investigation as a potential treatment for dry eye disease, a condition that affects millions of individuals worldwide. The extensive...

Continue Reading
Suunto's Innovative Race 2 Watch and Wing 2 Headphones Launch

Updated Category News Views 235

Suunto Unveils Race 2 Watch and Wing 2 Headphones Suunto, a leader in sports technology, has just introduced two exciting products aimed at enhancing the experiences of runners and fitness enthusiasts: the Suunto Race 2 trail running watch and the Wing 2 bone conduction headphones. These innovative devices are set to redefine performance, comfort, and safety, helping...

Continue Reading
Capgemini’s Insights on Energy Transition Challenges

Updated Category News Views 121

Capgemini’s World Energy Markets Observatory Annual Report Highlights The latest edition of Capgemini’s World Energy Markets Observatory (WEMO) reveals critical insights regarding the challenges faced in the global energy sector. Although there have been notable improvements in renewable energy development, the report underscores that the pace remains insufficient....

Continue Reading
Earnings Forecast for Interactive Brokers Group: What to Expect

Updated Category News Views 294

Anticipated Earnings from Interactive Brokers Group Interactive Brokers Gr (NASDAQ: IBKR) is scheduled to announce its quarterly earnings soon, and expectations are running high among investors. Analysts have estimated an earnings per share (EPS) of $0.52, a significant figure that could influence stock performance post-announcement. Earnings Expectations and Market...

Continue Reading
China's Commitment to Cultural Heritage Preservation Today

Updated Category News Views 278

In a world where rapid change is the norm, China’s commitment to cultural heritage preservation stands out. This isn’t just about keeping the past alive; it’s about safeguarding a legacy that stretches back thousands of years. Take the Mogao Grottoes near Dunhuang, for example. These caves aren’t just historical sites; they’re treasure troves of Buddhist art and...

Continue Reading